285 related articles for article (PubMed ID: 26002609)
1. De-escalation attempts for adjuvant trastuzumab: longer beats shorter.
Curigliano G; Goldhirsch A
Ann Oncol; 2015 Jul; 26(7):1275-6. PubMed ID: 26002609
[No Abstract] [Full Text] [Related]
2. T1 invasive breast lobular tumor and ductal carcinoma with HER-2 positive characteristics: Is it rationale to use adjuvant trastuzumab?
Altundag K
J BUON; 2017; 22(4):1083. PubMed ID: 28952233
[No Abstract] [Full Text] [Related]
3. Different adjuvant chemotherapy regimens in older breast cancer patients?
Wildiers H; Brain E
Ann Oncol; 2015 Apr; 26(4):613-615. PubMed ID: 25600566
[No Abstract] [Full Text] [Related]
4. Upfront adjuvant aromatase inhibitors in women with lobular breast cancer.
Montemurro F
Eur J Cancer; 2013 Oct; 49(15):3376-7. PubMed ID: 23867125
[No Abstract] [Full Text] [Related]
5. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; Prat A
Lancet Oncol; 2017 Apr; 18(4):545-554. PubMed ID: 28238593
[TBL] [Abstract][Full Text] [Related]
6. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning?
Rugo HS
J Clin Oncol; 2012 Mar; 30(9):898-901. PubMed ID: 22331930
[No Abstract] [Full Text] [Related]
8. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
9. Different outcome variables yield different results!
Brouckaert O; Wildiers H; Neven P
Ann Oncol; 2013 Feb; 24(2):554. PubMed ID: 23277485
[No Abstract] [Full Text] [Related]
10. Letter to the editor - author's response.
van de Water W; Fontein DB; van de Velde CJ
Eur J Cancer; 2013 Oct; 49(15):3378-9. PubMed ID: 23890770
[No Abstract] [Full Text] [Related]
11. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
12. A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.
Stoen E; Kabos P; Borden KC; Brown RJ; Borges VF; Diamond JR
Oncology (Williston Park); 2018 Jun; 32(6):298-302. PubMed ID: 29940061
[No Abstract] [Full Text] [Related]
13. Reply to 'Different outcome variables yield different results', by O. Brouckaert et al.
Truin W; Voogd AC; Roumen RMH
Ann Oncol; 2013 Feb; 24(2):555. PubMed ID: 23341480
[No Abstract] [Full Text] [Related]
14. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
15. [The requirements to clinicopathology about targeted therapy for breast cancer].
Jiang ZF; Shen G
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):435-7. PubMed ID: 17845752
[No Abstract] [Full Text] [Related]
16. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L
Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
18. Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
Alramadhan M; Ryu JM; Rayzah M; Nam SJ; Kim SW; Yu J; Lee SK; Bae SY; Park S; Paik HJ; Lee JE
Breast; 2016 Dec; 30():111-117. PubMed ID: 27697675
[TBL] [Abstract][Full Text] [Related]
19. [Response evaluation with mammography and ultrasound].
Junkermann H; Schmid H; Sinn HP; Wallwiener D
Zentralbl Gynakol; 1996; 118(10):572-3. PubMed ID: 8999712
[No Abstract] [Full Text] [Related]
20. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
